Ownership & Insider Lab

Look up a company to review current SEC-traceable insider positions, exact reporting-owner relationships across other published companies, a dated chronology of the published ownership evidence, and recent supported insider transactions where transaction history is separately available.
Coverage follows the existing reviewed company dataset and fails closed when a ticker is not currently supported.

Dianthus Therapeutics, Inc. /DE/ (DNTH)

Nasdaq · SEC CIK 0001690585

$5.79MCovered current disclosed holdings
1Covered reporting owners
1Covered direct positions
1Source ownership filings

This is the supported SEC-traceable subset, not total insider ownership or personal wealth. Values reflect the current disclosed positions Grizzly Bulls can resolve and value. Latest source filing: Aug 7, 2026 · values through Sep 25, 2026.

Covered reporting owners

Filter the reporting-owner snapshot by holder, role, or security. Position values are shown only where the current reviewed data supports them.

1 shown
HolderRolePositionCurrent valueLatest filing
Marino GarciaResearch disclosed relationshipsCEO AND PRESIDENT · Director65,292 sharesCommon Stock$5.79MAug 7, 2026

Reporting-owner research graph

These relationships are joined only when the same single SEC reporting-owner CIK appears unambiguously across the publication-authorized company ownership universe. Name similarity is never used to create a relationship.

This graph is bounded to the company ownership relationships currently published by Grizzly Bulls. It is not a complete employment, board, ownership, portfolio, or wealth history, and a missing relationship does not establish that none exists.

SEC transaction evidence ledger

Each row preserves the reviewed SEC transaction evidence, including the effective-date basis, amendment state, reported post-transaction position when present, and a separately published current covered owner/security position when one can be matched uniquely. Reported price is shown when present. The lab does not calculate gross proceeds, reconstruct balances between filings, or treat historical transactions as current wealth.

9 shown
Effective dateHolderActionSecurityUnitsReported priceReported position after transactionCurrent covered positionFiling
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsSaleSEC code SCommon Stock21,909 shares$108.7265,292 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsSaleSEC code SCommon Stock104,091 shares$107.9687,102 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsSaleSEC code SCommon Stock800 shares$110.76191,292 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsSaleSEC code SCommon Stock2,536 shares$110.02192,092 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsSaleSEC code SCommon Stock2,373 shares$109.1194,628 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsSaleSEC code SCommon Stock23,907 shares$108.05197,001 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsSaleSEC code SCommon Stock10,384 shares$107.49220,908 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsAcquisitionSEC code MCommon Stock126,000 shares$8.44231,292 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026
Aug 7, 2026Transaction dateMarino GarciaResearch disclosed relationshipsAcquisitionSEC code MCommon Stock40,000 shares$8.44105,292 shares65,292 sharesOwner coverage latest filing Aug 7, 20264Filed Aug 7, 2026

A reported post-transaction position is the balance stated in that historical transaction filing. A current covered position is a separate latest owner/security observation and may reflect later filings or activity. They are shown side by side as evidence points, not as a reconstructed continuous ledger.

Published 9 of 9 source candidates under the current reviewed security-resolution rules.

Covered securities

SecurityInstrument familyCovered positionsCovered value
Common Stockordinary-share1$5.79M

Coverage and interpretation

Current holdings: direct positions that the reviewed ownership data can trace to an exact reporting owner, legal security, and current-basis quantity.

Current value: the existing published company-position valuation. This lab does not recalculate security values or infer missing positions.

Transaction evidence: historical flow observations with filing provenance. Reported post-transaction balances and current covered positions are separate evidence points; the lab does not interpolate ownership between them.

Reporting-owner graph: exact reporting-owner CIK relationships across the published company universe. It does not merge people by name or create a complete personal history.

Not included here: a claim of total insider ownership, total personal wealth, institutional 13F ownership, a transaction-value estimate, an insider sentiment score, or an investment recommendation.

Published ownership evidence chronology

This sequence orders only the ownership evidence already published by Grizzly Bulls for the exact reporting-owner relationships above. Transaction rows are ordered by filing date while preserving the separate economic effective date and its basis. Current covered snapshots remain separate latest observations.

The chronology does not interpolate ownership between entries, infer missing activity, pair an amended filing with an assumed parent, infer amendment supersession, or treat a current covered snapshot as proof of continuous ownership.

Marino Garcia

SEC reporting-owner CIK 0001669866 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Aug 7, 2026Latest represented filing dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqCurrent covered snapshotCEO AND PRESIDENT · DirectorValuation observation Sep 25, 2026Common Stock: 65,292 sharesCurrent covered company value: $5.79MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqAcquisitionSEC code MEffective Aug 7, 2026 · transaction dateReported units 40,000 shares · reported price 8.44Common StockReported position after transaction: 105,292 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqAcquisitionSEC code MEffective Aug 7, 2026 · transaction dateReported units 126,000 shares · reported price 8.44Common StockReported position after transaction: 231,292 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqSaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 10,384 shares · reported price 107.49Common StockReported position after transaction: 220,908 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqSaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 23,907 shares · reported price 108.05Common StockReported position after transaction: 197,001 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqSaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 2,373 shares · reported price 109.1Common StockReported position after transaction: 194,628 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqSaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 2,536 shares · reported price 110.02Common StockReported position after transaction: 192,092 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqSaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 800 shares · reported price 110.76Common StockReported position after transaction: 191,292 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqSaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 104,091 shares · reported price 107.96Common StockReported position after transaction: 87,102 shares4 filing0001669866-26-000010
Aug 7, 2026Filed dateDianthus Therapeutics, Inc. /DE/ (DNTH)NasdaqSaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 21,909 shares · reported price 108.72Common StockReported position after transaction: 65,292 shares4 filing0001669866-26-000010

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 9 published transaction rows for this exact reporting-owner CIK appear in the chronology.

Continue this ownership research

These handoffs preserve the exact company identities already represented in the reporting-owner graph. My Stocks keeps a listed company in your existing research lists. Research Inbox is a separate company-change update workflow.

Saving a company to My Stocks never enables updates, and opening Research Inbox never subscribes you automatically. Each update remains an explicit company-level opt-in under the existing Research Inbox consent flow.

CompanyReporting-owner contextPublished evidenceContinue research
Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq · Current company10Published chronology observationsLatest represented evidence Aug 7, 2026

These are company-level continuation paths, not reporting-owner subscriptions. Saving or watching one company does not automatically save or watch the other companies connected to the same reporting owner, and it does not create an owner-level alert.